Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 180, Issue 2, Pages 271-275Publisher
WILEY
DOI: 10.1111/bjh.14970
Keywords
cardiotoxicity; cardio-oncology; proteasome inhibitor; immunomodulatory drugs; multiple myeloma
Categories
Ask authors/readers for more resources
Patients with multiple myeloma (MM) have improved treatment options, including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). Despite their efficacy, increased rates of cardiovascular (CV) complications occur in patients exposed to some of these therapies. While previous research has focused on identifying the toxicities inherent to each specific agent, the CV side effects may be potentiated by the combination of PIs and IMiDs plus dexamethasone. We present a patient with MM with recurrent cardiotoxicity only when exposed to combination PI and IMiD-based therapy. We also review the literature in this context, and propose a potential algorithm for cardiotoxicity prevention in this population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available